Takeda Pharmaceutical Company Ltd
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 246
- Registration Number
- NCT02181842
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Phase 3
Completed
- Conditions
- Multiple MyelomaAutologous Stem Cell Transplant
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 656
- Registration Number
- NCT02181413
- Locations
- π¦πΉ
Elisabethinen Hospital Linz, Linz, Austria
π¦π·Hospital Iturraspe, Santa Fe, Argentina
πΊπΈPenn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Azilsartan/Amlodipine
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1090
- Registration Number
- NCT02181816
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02176486
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02170220
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]
Completed
- Conditions
- Acute Stress Ulcer and Acute Gastric Mucosal Lesions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 63
- Registration Number
- NCT02170207
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11288
- Registration Number
- NCT02167893
Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14151
- Registration Number
- NCT02166697
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
Phase 1
Terminated
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Drug: TAK-137 Placebo
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 47
- Registration Number
- NCT02163915
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
Phase 2
Terminated
- Conditions
- Barrett's Esophagus
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6
- Registration Number
- NCT02162758
Β© Copyright 2025. All Rights Reserved by MedPath